TY - JOUR T1 - Human Monkeypox Virus outbreak among Men who have Sex with Men in Amsterdam and Rotterdam, the Netherlands: no evidence for undetected transmission prior to May 2022 in a retrospective study JF - medRxiv DO - 10.1101/2022.11.19.22282179 SP - 2022.11.19.22282179 AU - Henry J. de Vries AU - Hannelore M. Götz AU - Sylvia Bruisten AU - Annemiek A. van der Eijk AU - Maria Prins AU - Bas B. Oude Munnink AU - Matthijs R.A. Welkers AU - Marcel Jonges AU - Richard Molenkamp AU - Brenda M. Westerhuis AU - Leonard Schuele AU - Arjen Stam AU - Marjan Boter AU - Elske Hoornenborg AU - Daphne Mulders AU - Mariken van den Lubben AU - Marion Koopmans Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/11/20/2022.11.19.22282179.abstract N2 - Since May 2022 over 20.000 human monkeypox virus (hMPXV) cases have been reported from 29 EU/EEA countries, predominantly among men who have sex with men. With over 1200 cases, and a crude notification rate of 70.7 per million population, the Netherlands was in the top 5 European countries most affected. The first national case was reported from May 10th, yet potential prior transmission remains unknown. Insight into prolonged undetected transmission can help to understand the current outbreak dynamics and aid future public health interventions. We therefor performed a retrospective study to elucidate whether undetected transmission of hMPXV occurred prior to the first reported cases in Amsterdam and Rotterdam. In 401 anorectal- and ulcer samples from visitors of the Centers for Sexual Health of Amsterdam and Rotterdam dating back to February 14th, we identified 2 new cases, the earliest from the first week of May (week 18), 2022. This coincides with the first cases reported in the United Kingdom, Spain and Portugal. We found no evidence of widespread hMPXV transmission in Dutch sexual networks of MSM prior to May 2022. Likely, the hMPXV outbreak expanded across Europe within a short period in the spring of 2022 in an international highly intertwined network of sexually active MSM.Ethical statement The Amsterdam University Medical Centre Ethical committee approved the study and deemed a full review not necessary according to the Medical Research Involving Human Subjects Act (reference letter: W22_257 # 22.313, dd July 14, 2022). Samples included from Rotterdam were required to be collected more than 3 weeks prior to the analysis (i.e. the duration of quarantine in case of a positive result) as they were deemed to be of no consequence for the index or his/her contacts. All samples and collected data were fully de-identified before sample analysis assuring anonymity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Amsterdam University Medical Centre Ethical committee approved the study and deemed a full review not necessary according to the Medical Research Involving Human Subjects Act (reference letter: W22_257 # 22.313, dd July 14, 2022). Samples included from Rotterdam were required to be collected more than 3 weeks prior to the analysis (i.e. the duration of quarantine in case of a positive result) as they were deemed to be of no consequence for the index or his/her contacts. All samples and collected data were fully de-identified before sample analysis assuring anonymity.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://mpox.genspectrum.org https://github.com/nextstrain/monkeypox ER -